Comparing Medicare Drug Plans May Ease Prostate Cancer Financial Toxicity
Investigators examined a range of Medicare Part D plans for the out-of-pocket costs and financial toxicity of select prostate cancer drugs.
Source: empr.com
Stay updated with breaking news from Benjamin Pockros. Get real-time updates on events, politics, business, and more. Visit us for reliable news and exclusive interviews.
Investigators examined a range of Medicare Part D plans for the out-of-pocket costs and financial toxicity of select prostate cancer drugs.
Investigators examined a range of Medicare Part D plans for the out-of-pocket costs and financial toxicity of select prostate cancer drugs.
A free online tool could potentially save some prostate cancer patients more than $9,000 in out-of-pocket drug costs, a new study finds.
Analyzing recent reimbursement trends may help urology practices contextualize payment policy and prepare for upcoming financial changes.